HeartFlow Holding, a provider of precision heart care technology, announced that it and Longview Acquisition II have mutually agreed to terminate their previously announced business combination agreement, effective immediately, as a result of current unfavorable market conditions. The deal had valued the merged enterprise at a pro forma $2.4 billion.
Announced in July 2021, the transaction was expected to deliver up to $599 million of gross proceeds to HeartFlow from the $690 million cash in trust held by Longview.
HeartFlow technology uses artificial intelligence to create a personalized, three-dimensional model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. Read more.
